VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CRVL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CRVLCorVel Corporation
$61.65$3.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksCRVLBalance Sheet

CorVel Corporation (CRVL) Balance Sheet

30Y historyFree accessUpdated daily

The company maintains a robust financial position with a near-zero debt-to-equity profile and a consistent equity base expansion to $394.2M as of 2026Q4.

CRVL Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricMar'26Mar'25Mar'24Mar'23Mar'22Mar'21Mar'20Mar'19Mar'18Mar'17Mar'16Mar'15Mar'14Mar'13Mar'12Mar'11Mar'10Mar'09Mar'08Mar'07Mar'06Mar'05Mar'04Mar'03Mar'02Mar'01Mar'00Mar'99Mar'98Mar'97
Total Assets642.99M545.98M454.68M393.92M415.25M424.76M416.26M318.02M274M235.38M220.27M211.57M214.48M182.38M171.88M164.22M140.37M141.21M140.57M113.77M100.1M105.7M106.31M96.24M80.3M77.56M71.19M68.7M60.5M58.8M
Asset Growth %17.77%20.08%15.42%-5.13%-2.24%2.04%30.89%16.06%16.41%6.86%4.11%-1.36%17.6%6.11%4.66%17%-0.6%0.45%23.56%13.66%-5.3%-0.58%10.46%19.86%3.52%8.96%3.62%13.55%2.89%8.89%
Total Investment Assets0000000200K1.08M1.97M-7.91B1.4M-6.86B-6.45B5.82M5.28M000-5.15B0-4.15B-4.32B-5.03B000000
Long-Term Investments0000000200K1.08M1.97M01.4M000000000000000000
Short-Term Investments000000000000005.82M5.28M00000000000000
Total Current Assets462.3M386.69M302.23M243.77M264.99M268.94M208.99M215.49M163.32M128.87M123.11M112.05M120.96M92.9M81.25M82.34M67.15M65.3M66.39M64.29M60.47M63M63.86M61.07M51.18M50.37M47.28M44.7M37.2M39.8M
Cash & Equivalents233.07M170.58M105.56M71.33M97.5M139.72M83.22M91.71M55.77M28.61M32.78M25.52M34.87M19.82M6.6M12.27M10.24M14.68M17.91M15.02M14.21M8.95M8.64M5.91M12.6M9.46M5.64M9.1M8.4M15.7M
Receivables101.31M104.13M97.11M81.03M82.59M64.72M65.77M71.34M64.94M62.84M59.75M57.54M57.23M49.1M49.33M48.96M43.93M41.25M39.16M41.03M39.52M46.84M45.54M45.39M33.04M34.32M35.87M31.6M25.6M22.3M
Other Current Assets115.71M000000035.5M32.47M25.95M23.08M6.86M16.55M-5.82M9.41M6.55M4.53M4.08M5.15M4.52M4.56M4.32M5.03M4.24M4.13M5.76M4M3.2M1.8M
Goodwill & Intangibles37.08B37.25M37.63M38.06M38.48M38.92M39.35M39.79M40.23M40.66M41.1M41.55M42.01M42.48M42.96M43.39M42.9M42.35M39.66M24.31M12.62M12.64M12.56M8.87M000000
Goodwill36.81B36.81M36.81M36.81M36.81M36.81M36.81M36.81M36.81M36.81M36.81M36.81M36.81M36.81M36.81M36.77M35.99M34.85M31.88M22.34M12.62M12.64M00000000
Intangible Assets263M438K821K1.24M1.67M2.1M2.54M2.98M3.42M3.85M4.29M4.74M5.19M5.66M6.15M6.73M6.91M7.5M7.79M1.97M0012.56M8.87M000000
PP&E (Net)139.07M112.88M109.95M110.49M111.29M115.94M166.57M61.98M69.36M63.04M53.27M56.3M51.25M46.58M47.36M38.5M30.03M29.79M30.57M24.86M26.46M29.65M29.39M25.85M22.48M20.07M16.63M17.1M16.5M13.1M
Other Assets-37.04B454K1.32M1.38M481K345K1.35M-11.57M-10.91M-14.43M-11.44M-7.18B-6.86B-6.45B000113K0306K0403K504K458K6.64M7.13M7.28M6.9M6.8M5.9M
Total Liabilities248.75M223.99M207.03M191.75M202.85M204.36M226.55M123.21M102.83M96.74M88.32M83.65M87.96M70.98M61.5M64.59M44.64M44.91M44.2M34.57M32.06M32.1M28.69M29.02M19.31M18.85M15.89M15.5M14.7M12.7M
Total Debt20.69M28.08M31.4M33.76M43.14M54.66M98.32M00000000000000000000000
Net Debt-212.38M-142.5M-74.17M-37.57M-54.36M-85.05M15.1M-91.71M-55.77M-28.61M-32.78M-25.52M-34.87M-19.82M-6.6M-12.27M-10.24M-14.68M-17.91M-15.02M-14.21M-8.95M-8.64M-5.91M-12.6M-9.46M-5.64M-9.1M-8.4M-15.7M
Long-Term Debt000000000000000000000000000000
Short-Term Debt00000000000618K000000000000000000
Total Current Liabilities228.07M204.04M184.5M167.89M171.37M162.46M133.69M116.92M97.99M90.05M80.42M74.09M71.84M52.76M44.76M54.84M39.95M37.21M36.95M29.27M25.87M24.41M22.61M23.55M15.64M15.24M12.88M13M12.4M11.2M
Accounts Payable24.55M15.42M16.41M15.06M14.08M12.35M15.14M9.93M11.79M13.87M13.23M13.58M17.44M12.56M11.61M00014.07M13.42M13.71M12.29M10.77M9.79M3.43M3.01M5.31M6.5M6.1M6.6M
Deferred Revenue0132.28M118.1M107M95.58M79.01M66.64M62.17M50.81M42.57M33.47M25.05M21.8M14.35M8.6M0002.08M00000000000
Other Current Liabilities203.52M000000-4.16M1.67M00-618K000009.44M6.41M6.76M0000007.58M6.5M6.3M4.6M
Deferred Taxes00001000K01000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K
Other Liabilities000000000000000003.94B000000000000
Total Equity394.23M321.99M247.65M202.18M212.4M220.4M189.71M194.81M171.18M138.65M131.95M127.92M126.52M111.4M110.38M99.64M95.73M96.3M96.38M79.2M68.04M73.59M77.62M67.22M60.98M58.72M55.29M53.2M45.8M46.1M
Equity Growth %22.44%30.02%22.49%-4.81%-3.63%16.18%-2.61%13.8%23.46%5.08%3.15%1.11%13.57%0.92%10.78%4.09%-0.59%-0.08%21.69%16.4%-7.55%-5.19%15.47%10.23%3.86%6.19%3.93%16.16%-0.65%1.77%
Shareholders Equity394.23M321.99M247.65M202.18M212.4M220.4M189.71M194.81M171.18M138.65M131.95M127.92M126.52M111.4M110.38M99.64M95.73M96.3M96.38M79.2M68.04M73.59M77.62M67.22M60.98M58.72M55.29M53.2M45.8M46.1M
Minority Interest000000000000000000000000000000
Retained Earnings1.01B903.09M807.92M731.67M665.3M598.89M552.54M505.16M458.46M422.76M393.28M364.76M336.17M301.78M275.05M248.49M223.83M197.74M178.46M157.73M139.16M130.05M119.89M103.88M87.3M72.47M59.25M47.3M36.9M27.4M
Common Stock5K5K3K3K3K3K3K3K3K3K3K3K3K3K3K3K3K3K3K3K2K2K2M2M2K1K1K000
Accumulated OCI000000000-143.74M-130.74M0-109.29M0-91.1M-82.81M-77.59M-74.11M0-61.81M0-49.83M-44.53M-39.73M00-29.41M-23.3M-17.4M-12.7M
Return on Equity (ROE)30.81%33.41%33.9%32.02%30.69%22.61%24.64%25.52%23.04%21.79%21.95%22.47%28.91%24.1%25.29%25.25%27.18%20.01%26.64%25.23%13.77%13.43%22.11%25.87%24.76%23.19%22.06%21.01%20.67%18.6%
Return on Assets (ROA)18.56%19.02%17.97%16.4%15.81%11.02%12.9%15.78%14.01%12.94%13.21%13.42%17.33%15.09%15.8%16.19%18.54%13.68%18.39%17.37%9.48%9.58%15.81%18.79%18.78%17.78%17.11%16.1%15.93%15.07%
Equity / Assets61.31%58.97%54.47%51.32%51.15%51.89%45.58%61.26%62.47%58.9%59.9%60.46%58.99%61.08%64.22%60.67%68.2%68.19%68.56%69.61%67.97%69.63%73.01%69.85%75.95%75.7%77.67%77.44%75.7%78.4%
Debt / Equity0.05x0.09x0.13x0.17x0.20x0.25x0.52x-----------------------
Book Value per Share7.646.194.763.833.9111.8910.2310.258.997.086.606.121.991.501.491.341.291.301.140.930.780.780.810.690.600.560.500.480.420.36
Tangible BV per Share-710.565.474.043.113.209.798.118.166.885.014.544.131.330.930.910.760.710.730.670.640.630.640.680.600.600.560.500.480.420.36

Key Metrics

Growth RegimeExpanding
ProfitabilityStrong
Balance SheetFortress
Cash FlowRobust
Top Statement Risk

Medical labor cost inflation

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q4)

Consistent Equity Base Expansion Trend

As reported in financial statements, CorVel’s equity has grown from $233.5M in 2024Q3 to $394.2M by 2026Q4, reflecting a consistent internal capital generation trajectory that supports the company's ability to fund operations and strategic initiatives without relying on external debt financing or dilutive equity issuance.

The steady climb in total equity suggests that the company is successfully retaining earnings while simultaneously managing share repurchases. This trend indicates a strengthening balance sheet that provides a buffer against potential volatility in the workers' compensation claims environment.

Claims Reserve Growth Reflects Volume

Based on the provided quarterly data, claims reserves have increased from $160.1M in 2024Q3 to $185.5M in 2026Q4, which appears to track with the company's expanding service volume and the broader inflationary pressures currently affecting medical costs within the U.S. workers' compensation insurance market.

The rise in reserves is a logical consequence of higher claims processing activity rather than an indication of deteriorating loss development. Investors should monitor whether this growth in reserves continues to outpace revenue, which could suggest a shift in the underlying risk profile of the claims being managed.

Debt-Free Capital Structure Provides Optionality

According to the latest balance sheet figures, CorVel maintains a near-zero debt profile, which stands in stark contrast to industry peers and provides the company with significant financial flexibility to navigate potential market downturns or pursue opportunistic investments in proprietary technology without the burden of interest obligations.

This conservative capital structure is a hallmark of the company's long-term strategy, prioritizing balance sheet resilience over financial leverage. The absence of debt suggests that management is well-positioned to maintain its current pace of capital returns to shareholders while preserving capacity for future operational scaling.

Hidden Sensitivity to Medical Inflation

While the balance sheet appears robust, the company's reliance on specialized medical labor, as evidenced by the $185.5M in claims reserves, may expose the firm to significant margin compression if wage inflation for clinical staff continues to outpace the company's ability to adjust its service fee structures.

Investors should consider that the lack of debt does not insulate the company from operational risks related to medical labor costs. If the cost of providing managed care services rises faster than the savings generated for clients, the company's profitability may face headwinds despite its strong liquidity position.

CRVL — Frequently Asked Questions

Quick answers to the most common questions about buying CRVL stock.

What are the total assets of CorVel Corporation (CRVL)?

As of 2026, CorVel Corporation (CRVL) had total assets of $643.0M including $462.3M in current assets.

How much debt does CorVel Corporation (CRVL) have?

CorVel Corporation (CRVL) carries total debt of $20.7M, offset by $233.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of CorVel Corporation?

CorVel Corporation (CRVL) has total shareholders' equity (book value) of $394.2M ($7.64 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is CorVel Corporation's current ratio and liquidity?

CorVel Corporation (CRVL) reported a current ratio of 2.03x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.